Viktor Gruenwald, MD, PhD, discusses key results from a post hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma, highlighting the clinical implications of these results.
Deciphera Pharma (DCPH) Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib –
– Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib –
– Median.
PET imaging with 68Ga-FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in the December issue of The Journal of Nuclear Medicine.